Gracell Biotechnologies Investor Relations Material

Gracell Biotechnologies Inc. (GRCL) is a clinical-stage biopharmaceutical company primarily focused on discovering and developing innovative cell therapies for cancer treatment. The company leverages its proprietary FasTCAR and TruUCAR technology platforms, along with its SMART CART™ technology module, to develop therapies designed to offer fast, deep, and durable responses for patients suffering from cancer and autoimmune diseases. Gracell Biotechnologies is headquartered in Suzhou, China, and its shares are listed on the Nasdaq.